citations: 2
citations: 2
SDS-PAGE Analysis. Lane 1: MWM; Lane 2: 1.0 µg of purified IL-33 (human), (recombinant).
quantity: 3 x 10 µg
price:
to the supplier
citations: 1
Western Blot analysis: Lane 1: MW Marker; Lane 2: 100ng of purified IL-33 (mouse), (recombinant) protein probed with IL-33 mAb (Prod. no. ALX-804-840PF-C100) at 0.5ug/ml.
SDS-PAGE analysis: Lane 1: MW Marker; Lane 2: 1.0ug of purified IL-33 (mouse), (recombinant).
quantity: 10 µg
price:
to the supplier
Figure 2:a) Pull down assay of IL-33 (human) (His) (Prod. No. ALX-201-350) by ST2 (human):Fc (human) (rec.) (Prod. No. ALX-201-367).b) Pull down assay of ST2 (human):Fc (human) (rec.) by IL-33 (human) (His). Method: 5µg of ST2 (human):Fc (human) (rec.) (or control Fc protein), 2µg of IL-33 (human) (His) (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4°C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of IL-33 (human) (His) or ST2 (human):Fc (human) (rec.) with anti-His HRP or anti-human IgG HRP, respectively.
Figure 3: Activation of a human ST2-dependent NF-kappaB pathway using IL-33. Method: HEK 293 cells were transiently co-transfected with 500ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-kappaB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in 12-well plate. At 40 hours after transfection, cells were treated with IL-33 (human) (recombinant) (His) (Prod. No. ALX-201-350) at the concentration as indicated for 8 hours, followed by measurement of dual luciferase assay.
quantity: 10 µg
price:
to the supplier